Investment Rating - The report maintains an "Outperform" rating for the company [2][7]. Core Views - The maternity subsidy policy is expected to strengthen domestic demand for infant formula, leading to a recovery in sales [3][11]. - The company plans to invest 1.2 billion yuan in a nationwide birth subsidy program starting in April 2025, providing monthly subsidies of one can of infant formula for five months to new mothers [3][11]. - The new product Zhuo Rui has significantly outperformed older products, becoming the company's largest single product, with sales increasing over 60% year-on-year [4][12]. Financial Performance - The company achieved a revenue of 20.749 billion yuan in 2024, a year-on-year increase of 6.2%, with a net profit of 3.570 billion yuan, up 5.3% [4][12]. - The gross profit margin for 2024 was 66.3%, an increase of 1.5 percentage points year-on-year, attributed to reduced price promotions and lower raw material costs [5][13]. - The payout ratio for dividends was approximately 76% in 2024, with expectations for continued growth in absolute dividend amounts [6][14]. Earnings Forecast - Revenue projections for 2025-2027 are set at 22.11 billion, 23.75 billion, and 25.50 billion yuan, respectively, with corresponding net profits of 3.96 billion, 4.34 billion, and 4.65 billion yuan [7][15]. - The expected earnings per share (EPS) for 2025-2027 are 0.44, 0.48, and 0.51 yuan, respectively [7][15]. - The target price for the stock is set at HK$7.00, based on a price-to-earnings (P/E) ratio of 15 for 2025 [2][15].

研究报告 Research Report 14 Apr 2025 颐海国际 YIHAI INTERNATIONAL HOLDING (1579 HK) 率先布局海外蓄力，第三方客户提振业绩 Take the lead in laying out overseas, and third party boost performance [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$13.42 目标价 HK$16.55 HTI ESG 1.2-3.0-3.0 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$13.91bn / US$1.79bn 日交易额 (3 个月均值) US$10.32mn 发行股票数目 1,037mn 自由流通股 (%) 56% 1 年股价最高最低值 HK$18.28-HK$10.62 注：现价 HK$13.42 为 2025 年 04 月 11 日收盘 ...

Investment Rating - The investment rating for the company is "Buy" with a target price of HKD 16.00 [6][7]. Core Views - The company expects a net profit growth of 80% to 100% year-on-year for Q1 2025, driven by reduced disaster impacts and improved underwriting profits [1]. - The overall cost ratio (COR) for both auto and non-auto insurance segments is expected to improve due to lower claims and effective cost management strategies [2][3]. - The company's investment income has significantly increased due to a strategic allocation in high-quality equity assets, with notable performance from major holdings like Industrial Bank [4]. Summary by Sections Q1 2025 Performance - The company anticipates a substantial increase in net profit for Q1 2025, attributed to a decrease in disaster-related claims and enhanced operational efficiency [1]. - The comprehensive cost ratio is projected to decline, leading to a significant rise in underwriting profits [1]. Auto Insurance Segment - The auto insurance COR is expected to slightly decrease, with a projected COR of 95.9% for 2025, supported by a 4.4% year-on-year growth in premium income [2]. - The company is focusing on risk reduction services and adjusting its business structure to maintain steady growth in auto insurance premiums [2]. Non-Auto Insurance Segment - The non-auto insurance COR is forecasted to improve slightly, with an estimated COR of around 99% for 2025, following a rise in claims in 2024 [3]. - Premium income for non-auto insurance is expected to grow by 7.6% year-on-year, outpacing the growth in auto insurance [3]. Investment Income - The company has seen a significant increase in total investment income, with a focus on value investing and a strategic increase in high-quality equity assets [4]. - The performance of key holdings, particularly Industrial Bank, has contributed positively to the investment income growth [4]. Earnings Forecast and Valuation - The EPS estimates for 2025, 2026, and 2027 have been adjusted to RMB 1.74, RMB 1.67, and RMB 1.79 respectively, reflecting a positive outlook on underwriting performance [5]. - The target price has been raised to HKD 16.00 based on DCF valuation methods, indicating a favorable investment opportunity [5].

Investment Rating - The report maintains a "Buy" rating for Zai Lab (09688.HK) [2] Core Views - Zai Lab's drug Efgartigimod shows strong potential in the treatment of Myasthenia Gravis (MG) with rapid onset and long-term efficacy, establishing its position as a Best-in-Class (BIC) therapy [8][11] - The FDA has approved the pre-filled subcutaneous injection form of Efgartigimod, enhancing its competitive edge in the market [25][26] - The company is expected to achieve significant revenue growth, with projected revenues of $564 million in 2025 and $1.357 billion in 2027, reflecting growth rates of 41.35% and 62.46% respectively [7][40] Summary by Sections Market Performance - Zai Lab's stock price is currently at HKD 22.20, with a market capitalization of HKD 24.45 billion [2][7] Financial Data and Forecast - Total shares outstanding: 1,101.28 million - Revenue projections: $267 million in 2023, $399 million in 2024, $564 million in 2025, $835 million in 2026, and $1.357 billion in 2027 - Net profit projections: -$335 million in 2023, -$257 million in 2024, -$166 million in 2025, $17 million in 2026, and $168 million in 2027 - Gross margin expected to improve from 62.94% in 2024 to 69.45% in 2027 [7][40] Drug Development Insights - Efgartigimod has shown rapid efficacy in clinical trials, with 40% of patients achieving minimal symptom expression (MSE) within the first treatment cycle [8][14] - Long-term studies indicate consistent efficacy and safety, with 89% of patients showing significant improvement after 11 treatment cycles [21][22] - The drug is positioned to treat multiple autoimmune diseases, expanding its market potential beyond MG [37][32] Competitive Landscape - Despite the emergence of several competing biologics in the MG treatment space, Efgartigimod's sales growth remains robust, with projected global sales of approximately $2.2 billion in 2024 [32][34]

[Table_Main] 证券研究报告 | 公司点评 再鼎医药(09688.HK) 2025 年 04 月 14 日 买入（维持） 所属行业：医疗保健业/药品及生物科技 当前价格(港币)：22.20 元 证券分析师 周新明 资格编号：S0120524060001 邮箱：zhouxm＠tebon.com.cn 李霁阳 资格编号：S0120523080003 邮箱：lijy7＠tebon.com.cn 市场表现 -31% 0% 31% 63% 94% 126% 157% 188% 2024-04 2024-08 2024-12 再鼎医药 恒生指数 | 恒 生 指 数 对 | 1M | 2M | 3M | | --- | --- | --- | --- | | 比 | | | | | 绝对涨幅(%) | -18.83 | 5.21 | 17.34 | | 相对涨幅(%) | -7.45 | 9.53 | 7.63 | | 资料来源：德邦研究所，聚源数据 | | | | 重症肌无力领域近期新药进展众多，我们认为艾加莫德作为 BIC，在 MG 治疗领 域地位难以被撼动。 1）快速起效，快速达标：越来越多的临床试验使用基 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is expected to achieve stable growth supported by an expanding management scale, with a projected management area growth of 7.4% year-on-year to 431.1 million square meters by the end of 2024 [5][6] - Profit margins are anticipated to stabilize from 2025 to 2027, with net profit expected to grow at a high single-digit rate during this period [5][6] - The target price remains unchanged at HKD 6.30, indicating a potential upside of 18.6% from the current price [1][5] Financial Summary - Revenue projections for the company are as follows: - 2023: RMB 13,051 million - 2024: RMB 14,024 million (up 7.5% year-on-year) - 2025E: RMB 15,227 million (up 8.6% year-on-year) [4][10] - Core profit estimates are: - 2023: RMB 1,343 million - 2024: RMB 1,511 million (up 12.5% year-on-year) - 2025E: RMB 1,651 million (up 9.3% year-on-year) [4][10] - The company’s gross margin is expected to rebound to 16.6% in 2024, with a stable range of 16-17% projected for 2025-2027 [5][6] Share Performance - The stock has shown a year-to-date change of 3.71% and has a market capitalization of approximately HKD 17,437.83 million [3][4]

Investment Rating - The report maintains a BUY rating for Anta Sports, with a target price trimmed to HK$ 119.08, based on a 24x FY25E P/E ratio [1][3]. Core Insights - The acquisition of Jack Wolfskin is viewed positively, with the acquisition price considered attractive and significant potential for expansion in the mid-priced outdoor industry and European markets [1][11]. - Despite a slight decline in retail sales growth in March-April 2025, the outlook for Q2 2025 remains cautiously optimistic due to various growth drivers [11][12]. - The company's retail sales growth in Q1 2025 was satisfactory, with improvements in inventory management and a better-than-expected profit margin [10][11]. Financial Summary - Revenue projections for FY25E are set at RMB 78,235 million, with a year-on-year growth of 10.5% [2][12]. - Net profit for FY25E is estimated at RMB 14,961.4 million, reflecting a decrease of 12.7% year-on-year [2][12]. - The earnings per share (EPS) for FY25E is projected at RMB 4.66, down from RMB 5.34 in FY24A [2][12]. Market Performance - The current market capitalization of Anta Sports is approximately HK$ 226.67 billion, with a current stock price of HK$ 83.85, indicating a potential upside of 42% to the target price [3][4]. - The stock is trading at a P/E ratio of 17x for FY25E, which is considered attractive compared to its 5-year average of 25x [1][12]. Acquisition Details - Anta Sports announced the acquisition of Jack Wolfskin for USD 290 million (approximately RMB 23.5 billion), with expected sales of EUR 325 million and adjusted EBITDA of EUR 12 million for FY25E [11][18]. - The valuation metrics for the acquisition indicate a P/S ratio of approximately 0.8x, which is lower than both Anta's group average and the global sports industry average [11][18].

Investment Rating - The report maintains a "BUY" rating for BOE Varitronix, indicating a potential return of over 15% over the next 12 months [10][20]. Core Insights - The management believes that the recent US reciprocal tariffs will have a limited impact on financials due to low US sales exposure, which is only 2.6% in FY23 [9][10]. - BOE Varitronix is optimistic about the ramp-up of capacity in Vietnam by 2025 and has already secured orders from US and South Korean customers [9]. - The company plans to focus on overseas market expansion and adjust its product mix to mitigate tariff risks in the long term [9][10]. - A share repurchase plan announced on April 11 demonstrates management's confidence in the business outlook [9]. Financial Summary - Revenue is projected to grow from HK$10,760 million in FY23A to HK$22,228 million in FY27E, reflecting a CAGR of approximately 14.6% [2][17]. - Net profit is expected to recover from HK$391.3 million in FY24A to HK$738.7 million in FY27E, with a notable growth of 29.4% in FY25E [2][17]. - The company’s P/E ratio is forecasted to decrease from 10.1x in FY24A to 5.4x in FY27E, indicating an attractive valuation [2][10]. Target Price and Upside Potential - The target price for BOE Varitronix is set at HK$9.63, representing an upside potential of 91.8% from the current price of HK$5.02 [3][10]. Share Performance and Market Data - The market capitalization of BOE Varitronix is approximately HK$3,975.8 million, with an average turnover of HK$35.3 million over the last three months [4]. - The stock has experienced a decline of 30.9% over the past month and 17.4% over the past three months [6].

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is expected to experience stable growth supported by an expanding management scale, with a projected management area growth of 7.4% year-on-year to 431.1 million square meters by the end of 2024 [5][6] - Profit margins are anticipated to stabilize from 2025 to 2027, with net profit expected to grow at a high single-digit rate during this period [5] - The target price for the company is set at HKD 6.30, indicating a potential upside of 18.6% from the current price of HKD 5.31 [1][5] Financial Overview - Revenue projections for the company are as follows: - 2023: RMB 13,051 million - 2024: RMB 14,024 million (growth of 7.5%) - 2025: RMB 15,227 million (growth of 8.6%) - 2026: RMB 16,127 million (growth of 5.9%) - 2027: RMB 16,958 million (growth of 5.2%) [4][10] - Core profit estimates are: - 2023: RMB 1,343 million - 2024: RMB 1,511 million (growth of 12.5%) - 2025: RMB 1,651 million (growth of 9.3%) - 2026: RMB 1,750 million (growth of 6.0%) - 2027: RMB 1,855 million (growth of 6.0%) [4][10] - The company’s net profit is projected to increase from approximately RMB 1.51 billion in 2024 to RMB 1.86 billion in 2027 [5][10] Market Performance - The stock has shown a year-to-date change of 3.71% and has a market capitalization of approximately HKD 17,437.83 million [3][4] - The 52-week high and low for the stock are HKD 7.12 and HKD 4.05, respectively [3]

Investment Rating - The investment rating for Geely Automobile is "Buy" and is maintained [6]. Core Views - Geely Automobile's Q1 2025 performance is expected to exceed expectations, driven by strong sales in the new energy vehicle segment, with projected net profit before accounting policy changes estimated at 11.6-12.3 billion yuan, representing a year-on-year increase of 640%-690% [2][4]. - The company is entering a new product era supported by the GEA architecture, with positive developments across its brands including Zeekr, Lynk & Co, and Galaxy [2][8]. - The transition to new energy is progressing smoothly, with scale effects expected to enhance profitability, while the solid foundation of fuel vehicles and innovative overseas expansion strategies are opening new markets [8]. Summary by Sections Financial Performance - In Q1 2025, Geely is expected to achieve sales of 704,000 vehicles, a year-on-year increase of 47.9% and a quarter-on-quarter increase of 2.5%, marking a historical quarterly high [8]. - The projected net profit after accounting policy changes is estimated at 5.2-5.8 billion yuan, reflecting a year-on-year increase of 220%-270% [4][8]. - The single vehicle profit is expected to be between 0.74-0.82 million yuan, showing significant improvement [8]. Product Strategy - Geely plans to launch 10 new energy models in 2025, with various new and updated models across its brands [8]. - The company is focusing on both electrification and intelligence, with a significant increase in the adoption of intelligent driving capabilities [8]. Market Position - The new energy transition is accelerating profitability, with structural optimization and scale effects further enhancing profit margins [8]. - Geely's strong new vehicle cycle is expected to provide substantial profit elasticity, with a projected net profit of 16.1 billion yuan for 2025, corresponding to a PE ratio of 8.7X [8].